CVS Health (CVS)
(Delayed Data from NYSE)
$57.40 USD
-0.28 (-0.49%)
Updated May 20, 2024 04:00 PM ET
Pre-Market: $57.47 +0.07 (0.12%) 9:08 AM ET
5-Strong Sell of 5 5
A Value A Growth C Momentum A VGM
CVS Health (CVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$72.36 | $101.00 | $58.00 | 26.06% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for CVS Health comes to $72.36. The forecasts range from a low of $58.00 to a high of $101.00. The average price target represents an increase of 26.06% from the last closing price of $57.40.
Analyst Price Targets (22)
Broker Rating
CVS Health currently has an average brokerage recommendation (ABR) of 1.94 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.63 a month ago based on 23 recommendations.
Of the 24 recommendations deriving the current ABR, 11 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 45.83% and 12.5% of all recommendations. A month ago, Strong Buy made up 60.87%, while Buy represented 13.04%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 14 | 14 | 15 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 10 | 10 | 6 | 6 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.94 | 1.94 | 1.63 | 1.63 | 1.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | Argus Research Corp. | Christopher Graja | Not Available | Strong Buy |
5/2/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
5/2/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
5/1/2024 | SVB Securities | Michael Cherny | Strong Buy | Hold |
5/1/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Hold |
5/1/2024 | Evercore Partners | Elizabeth Anderson | Strong Buy | Strong Buy |
5/1/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
3/15/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
2/7/2024 | Edward D. Jones & Company | John Boylan | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.94 |
ABR (Last week) | 1.94 |
# of Recs in ABR | 24 |
Average Target Price | $72.36 |
LT Growth Rate | 14.90% |
Industry | Retail - Pharmacies and Drug Stores |
Industry Rank by ABR | 233 of 252 |
Current Quarter EPS Est: | 1.82 |